{"id":5657,"date":"2024-02-14T06:05:08","date_gmt":"2024-02-14T12:05:08","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5657"},"modified":"2025-06-27T11:21:28","modified_gmt":"2025-06-27T16:21:28","slug":"nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/","title":{"rendered":"El nanoscopio moderar\u00e1 los debates en la 4\u00aa Cumbre Anual de Comparabilidad de Terapia G\u00e9nica"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><strong>dallas, <\/strong>14 de febrero de 2024 - <a href=\"https:\/\/nanostherapeutics.com\/es\/\">Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda en fase cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina, se complace en anunciar su participaci\u00f3n en la 4\u00aa <a href=\"https:\/\/genetherapy-comparability.com\/\">Cumbre anual de comparabilidad de terapias g\u00e9nicas<\/a> que tendr\u00e1 lugar del 13 al 15 de febrero de 2024 en Boston. La cumbre de este a\u00f1o se centrar\u00e1 en implementar estudios de comparabilidad efectivos para superar obst\u00e1culos estrat\u00e9gicos y t\u00e9cnicos y acelerar la aprobaci\u00f3n de nuevas terapias gen\u00e9ticas.<\/p>\n<p>Samarendra Mohanty, PhD, presidenta y directora cient\u00edfica de Nanoscope, presidir\u00e1 el evento. En su presentaci\u00f3n y en una sesi\u00f3n, el Dr. Mohanty ofrecer\u00e1 informaci\u00f3n sobre c\u00f3mo afrontar las modificaciones de procesos y estrategias con visi\u00f3n de futuro en la transici\u00f3n a procesos comercialmente viables, garantizando al mismo tiempo la comparabilidad.<\/p>\n<p><strong>Los detalles de la presentaci\u00f3n son los siguientes:<br \/>\n<\/strong><strong>Sesi\u00f3n: <\/strong>Innovaciones en el desarrollo de procesos de terapia g\u00e9nica para ayudar a la comparabilidad<br \/>\n<strong>T\u00edtulo:<\/strong> Charla informal: c\u00f3mo navegar por los cambios en los procesos y garantizar pruebas integrales para minimizar los desaf\u00edos en la comparabilidad de las terapias g\u00e9nicas<br \/>\n<strong>Fecha:<\/strong> mi\u00e9rcoles, 14 de febrero de 2024<br \/>\n<strong>Tiempo:<\/strong> 3:30 pm hora del este<\/p>\n<p><strong>Sesi\u00f3n:<\/strong> Profundizar en los desaf\u00edos anal\u00edticos para superar los problemas de comparabilidad<br \/>\n<strong>T\u00edtulo:<\/strong> Superando los desaf\u00edos en los env\u00edos de paquetes de CMC<br \/>\n<strong>Fecha:<\/strong> jueves, 15 de febrero de 2024<br \/>\n<strong>Tiempo:<\/strong> 11:30 am hora del este<\/p>\n<p>Nanoscope sigue comprometido a ampliar los l\u00edmites de la terapia g\u00e9nica para mejorar los resultados de los pacientes y anticipa con impaciencia debates estimulantes con colegas estimados en esta reuni\u00f3n.<\/p>\n<p>Para m\u00e1s detalles y registrarse, visite <a href=\"https:\/\/genetherapy-comparability.com\/\">https:\/\/genetherapy-comparability.com\/<\/a><\/p>\n<p><strong>Acerca de Nanoscope Therapeutics, Inc.<br \/>\n<\/strong>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina para las que no existe cura. El activo principal de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados principales del ensayo cl\u00ednico RESTORE Fase 2b, multic\u00e9ntrico, aleatorizado, de doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04945772?term=Nanoscope&draw=2\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05417126?term=nanoscope&draw=2&rank=3\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><strong>Contacto de inversores:<\/strong><br \/>\nSocios Argot<br \/>\n212-600-1902<br \/>\n<a href=\"mailto:PR@nanostherapeutics.com\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>Dallas, February 14, 2024 \u2014 Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, is pleased to announce its role at the 4th Annual Gene Therapy Comparability Summit taking place February 13-15, 2024, in Boston. This year\u2019s summit will focus on implementing effective comparability studies to overcome strategic and technical [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5660,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-14T12:05:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:21:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit\",\"datePublished\":\"2024-02-14T12:05:08+00:00\",\"dateModified\":\"2025-06-27T16:21:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/\"},\"wordCount\":327,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_GeneTherapyComparability.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/\",\"name\":\"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_GeneTherapyComparability.jpg\",\"datePublished\":\"2024-02-14T12:05:08+00:00\",\"dateModified\":\"2025-06-27T16:21:28+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_GeneTherapyComparability.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_GeneTherapyComparability.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/14\\\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope moderar\u00e1 los debates en la 4\u00aa Cumbre Anual de Comparabilidad de la Terapia G\u00e9nica - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-02-14T12:05:08+00:00","article_modified_time":"2025-06-27T16:21:28+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit","datePublished":"2024-02-14T12:05:08+00:00","dateModified":"2025-06-27T16:21:28+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/"},"wordCount":327,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/","url":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/","name":"Nanoscope moderar\u00e1 los debates en la 4\u00aa Cumbre Anual de Comparabilidad de la Terapia G\u00e9nica - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","datePublished":"2024-02-14T12:05:08+00:00","dateModified":"2025-06-27T16:21:28+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_GeneTherapyComparability.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/14\/nanoscope-to-moderate-discussions-at-the-4th-annual-gene-therapy-comparability-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5657"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5657\/revisions"}],"predecessor-version":[{"id":9053,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5657\/revisions\/9053"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5660"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}